Amicus Therapeutics, Inc. (0HF9.L)
USD 7.2
(-2.69%)
USD 7.2
(-2.69%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 617.7 Million USD | 2.76% |
| 2022 | 601.12 Million USD | 0.56% |
| 2021 | 597.77 Million USD | -0.39% |
| 2020 | 600.14 Million USD | 60.56% |
| 2019 | 373.78 Million USD | -16.39% |
| 2018 | 447.03 Million USD | 63.05% |
| 2017 | 274.17 Million USD | -59.48% |
| 2016 | 676.69 Million USD | 20.72% |
| 2015 | 560.55 Million USD | 538.52% |
| 2014 | 87.78 Million USD | 7.31% |
| 2013 | 81.81 Million USD | 100.19% |
| 2012 | 40.86 Million USD | 1.65% |
| 2011 | 40.2 Million USD | -15.57% |
| 2010 | 47.61 Million USD | 251.76% |
| 2009 | 13.53 Million USD | -76.55% |
| 2008 | 57.73 Million USD | -9.51% |
| 2007 | 63.8 Million USD | -53.49% |
| 2006 | 137.16 Million USD | 112.65% |
| 2005 | 64.49 Million USD | 0.0% |
| 2003 | 5.77 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 616.96 Million USD | 4.38% |
| 2024 Q1 | 591.09 Million USD | -4.31% |
| 2023 Q1 | 597.94 Million USD | -0.53% |
| 2023 Q2 | 618.51 Million USD | 3.44% |
| 2023 Q3 | 630.84 Million USD | 1.99% |
| 2023 Q4 | 617.7 Million USD | -2.08% |
| 2023 FY | 617.7 Million USD | 2.76% |
| 2022 Q4 | 601.12 Million USD | -4.12% |
| 2022 Q2 | 627.16 Million USD | 6.6% |
| 2022 Q3 | 626.96 Million USD | -0.03% |
| 2022 Q1 | 588.32 Million USD | -1.58% |
| 2022 FY | 601.12 Million USD | 0.56% |
| 2021 Q3 | 580.04 Million USD | 1.23% |
| 2021 FY | 597.77 Million USD | -0.39% |
| 2021 Q2 | 572.98 Million USD | 2.48% |
| 2021 Q4 | 597.77 Million USD | 3.06% |
| 2021 Q1 | 559.13 Million USD | -6.83% |
| 2020 FY | 600.14 Million USD | 60.56% |
| 2020 Q1 | 335.75 Million USD | -10.17% |
| 2020 Q2 | 340.49 Million USD | 1.41% |
| 2020 Q3 | 580.27 Million USD | 70.42% |
| 2020 Q4 | 600.14 Million USD | 3.42% |
| 2019 Q3 | 334.02 Million USD | 5.05% |
| 2019 Q1 | 313.03 Million USD | -29.98% |
| 2019 FY | 373.78 Million USD | -16.39% |
| 2019 Q2 | 317.97 Million USD | 1.58% |
| 2019 Q4 | 373.78 Million USD | 11.9% |
| 2018 Q4 | 447.03 Million USD | 4.54% |
| 2018 Q3 | 427.63 Million USD | 61.99% |
| 2018 Q2 | 263.99 Million USD | -24.22% |
| 2018 Q1 | 348.38 Million USD | 27.07% |
| 2018 FY | 447.03 Million USD | 63.05% |
| 2017 Q1 | 682.6 Million USD | 0.87% |
| 2017 FY | 274.17 Million USD | -59.48% |
| 2017 Q4 | 274.17 Million USD | 1.13% |
| 2017 Q3 | 271.09 Million USD | -59.66% |
| 2017 Q2 | 672.07 Million USD | -1.54% |
| 2016 Q1 | 551.27 Million USD | -1.65% |
| 2016 Q3 | 581.62 Million USD | 0.32% |
| 2016 Q4 | 676.69 Million USD | 16.35% |
| 2016 FY | 676.69 Million USD | 20.72% |
| 2016 Q2 | 579.76 Million USD | 5.17% |
| 2015 Q1 | 88.6 Million USD | 0.93% |
| 2015 Q4 | 560.55 Million USD | -7.79% |
| 2015 Q3 | 607.93 Million USD | 710.46% |
| 2015 FY | 560.55 Million USD | 538.52% |
| 2015 Q2 | 75.01 Million USD | -15.34% |
| 2014 Q3 | 82.21 Million USD | 0.64% |
| 2014 Q4 | 87.78 Million USD | 6.79% |
| 2014 Q2 | 81.68 Million USD | 0.51% |
| 2014 FY | 87.78 Million USD | 7.31% |
| 2014 Q1 | 81.27 Million USD | -0.66% |
| 2013 Q3 | 42.61 Million USD | -0.37% |
| 2013 Q4 | 81.81 Million USD | 91.97% |
| 2013 Q1 | 39.87 Million USD | -2.42% |
| 2013 Q2 | 42.77 Million USD | 7.26% |
| 2013 FY | 81.81 Million USD | 100.19% |
| 2012 Q3 | 41.45 Million USD | 7.86% |
| 2012 Q2 | 38.43 Million USD | -3.98% |
| 2012 FY | 40.86 Million USD | 1.65% |
| 2012 Q1 | 40.02 Million USD | -0.44% |
| 2012 Q4 | 40.86 Million USD | -1.41% |
| 2011 Q2 | 45.68 Million USD | -7.7% |
| 2011 FY | 40.2 Million USD | -15.57% |
| 2011 Q4 | 40.2 Million USD | -4.46% |
| 2011 Q3 | 42.07 Million USD | -7.89% |
| 2011 Q1 | 49.49 Million USD | 3.93% |
| 2010 Q4 | 47.61 Million USD | 258.81% |
| 2010 FY | 47.61 Million USD | 251.76% |
| 2010 Q2 | 10.52 Million USD | -24.52% |
| 2010 Q3 | 13.27 Million USD | 26.1% |
| 2010 Q1 | 13.94 Million USD | 3.0% |
| 2009 FY | 13.53 Million USD | -76.55% |
| 2009 Q4 | 13.53 Million USD | -78.07% |
| 2009 Q3 | 61.73 Million USD | 2.82% |
| 2009 Q2 | 60.03 Million USD | 6.98% |
| 2009 Q1 | 56.11 Million USD | -2.79% |
| 2008 Q3 | 60.15 Million USD | -2.06% |
| 2008 Q1 | 61.84 Million USD | -3.06% |
| 2008 Q4 | 57.73 Million USD | -4.02% |
| 2008 Q2 | 61.41 Million USD | -0.7% |
| 2008 FY | 57.73 Million USD | -9.51% |
| 2007 FY | 63.8 Million USD | -53.49% |
| 2007 Q3 | 11.14 Million USD | 24.96% |
| 2007 Q2 | 8.91 Million USD | -94.4% |
| 2007 Q1 | 159.33 Million USD | 16.16% |
| 2007 Q4 | 63.8 Million USD | 472.51% |
| 2006 FY | 137.16 Million USD | 112.65% |
| 2006 Q4 | 137.16 Million USD | 0.0% |
| 2005 FY | 64.49 Million USD | 0.0% |
| 2005 Q4 | 64.49 Million USD | 0.0% |
| 2003 FY | 5.77 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | 1.012% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -389.858% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -133.33% |
| bluebird bio, Inc. | 424.62 Million USD | -45.471% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -798.364% |
| Imunon, Inc. | 8.53 Million USD | -7141.208% |
| Editas Medicine, Inc. | 150.05 Million USD | -311.65% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 96.997% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 82.379% |
| Myriad Genetics, Inc. | 312.9 Million USD | -97.413% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 39.405% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -26.719% |
| Verastem, Inc. | 71.18 Million USD | -767.747% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.103% |
| Waters Corporation | 3.47 Billion USD | 82.232% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 98.809% |
| Biogen Inc. | 12.04 Billion USD | 94.872% |
| Nektar Therapeutics | 267.04 Million USD | -131.311% |
| Perrigo Company plc | 6.04 Billion USD | 89.775% |
| Dynavax Technologies Corporation | 375.02 Million USD | -64.711% |
| Illumina, Inc. | 4.36 Billion USD | 85.852% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -1655.988% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -215.578% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -140.841% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -1556.404% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 67.318% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -649.343% |
| Evolus, Inc. | 209.68 Million USD | -194.585% |
| Adicet Bio, Inc. | 37.12 Million USD | -1564.079% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -1435.589% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 91.309% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 6.52% |
| FibroGen, Inc. | 585.72 Million USD | -5.46% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 87.44% |
| OPKO Health, Inc. | 622.47 Million USD | 0.767% |
| Homology Medicines, Inc. | 118.53 Million USD | -421.126% |
| Geron Corporation | 146.12 Million USD | -322.719% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 84.75% |
| Exelixis, Inc. | 678.44 Million USD | 8.953% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -2977.605% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -4828.243% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -146.286% |
| Zoetis Inc. | 9.29 Billion USD | 93.354% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -55.492% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -1156.113% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 88.005% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1175.067% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 76.273% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 74.318% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -438.015% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 62.551% |
| Blueprint Medicines Corporation | 918.64 Million USD | 32.759% |
| Insmed Incorporated | 1.66 Billion USD | 62.828% |
| TG Therapeutics, Inc. | 169.08 Million USD | -265.323% |
| Incyte Corporation | 1.59 Billion USD | 61.206% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 47.899% |